Application No. 10/821,925 Amendment dated October 3, 2005

Reply to Office Action of May 3, 2005

Docket No.: 4866-0101PUS1

Page 4 of 14

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A biodegradable common bile duct stent for

longitudinal and tranverse incisions at multiple parts of a common bile duct or a

common hepatic duct,

wherein the stent includes a tube structure with thin and continuous walls,

and includes an outer shape substantially equal to an anatomical shape of the

common bile duct,

wherein the stent is formed with multiple parts, each of the multiple parts

having an outer diameter substantially equal to 1 to 3 times an inner diameter of

corresponding parts of the common bile duct of a healthy person,

wherein the said stent is made of biodegradable polymeric material with

incorporation -of-including X-ray opaque components; the wall of the stent is thin and

the outer diameters of various parts of the stent are 1-3 times of the inner diameters

of the corresponding parts of the common bile duct of a healthy person; and the said

stent is fabricated according to the anatomic shape of common bile duct, and thus is

suitable for longitudinal or transverse incisions at various parts of common bile duct

and common hepatic duct.

2. (Currently Amended) The stent according to Claim 1, wherein the stent has

a shape selected from the group consisting of a straight tube, Y-shape-a Y-shaped

tube, fork-shape a fork-shaped tube, vest-shape a vest-shaped tube, and a short tube.

3. (Original) The stent according to Claim 1, wherein the stent has a length in

Birch, Stewart, Kolasch & Birch, LLP

Application No. 10/821,925 Amendment dated October 3, 2005

Reply to Office Action of May 3, 2005

Docket No.: 4866-0101PUS1

Page 5 of 14

the range of 10-80 mm and thickness of the wall in the range of 0.2-2 mm.

4. (Original) The stent according to Claim 1, wherein the said biodegradable

polymers are selected from the a group consisting of a poly(lactic acid), poly(glycollic

acid) a poly(glycolic acid), a poly(\varepsilon-caprolactone) and a random or a block copolymer of

lactic acid, glycollic acid-a glycolic acid, and an \(\epsilon\)-caprolactone.

5. (Currently Amended) The stent according to Claim 1, wherein the said X-ray

opaque components comprise barium sulfate and inorganic salts or oxides of bismuth,

tantalum or tungsten, and the an amount of the X-ray opaque components is between

5 and 50 % by weight based on the a weight of the stent.

6. (Cancelled)

7. (Currently Amended) The stent according to Claim 1, wherein the said

continuous wall of the stent has an outer surface comprising multiple protruding rims

separated by a distance of between 5 and 10 mm, wherein the cross section of ring

ring-shaped rims is in a form of square with round angles, and wherein the width and

height of the ring-ring-shaped rims are 1-2 mm, respectively.

8. (Currently Amended) The stent according to Claim 1 Claim 2, wherein the

wall structure of the stent is fabricated into the a shape similar to that of a larynx

duct, the a length of a larynx segmentum is being 5-20 mm, the a variation range of

Birch, Stewart, Kolasch & Birch, LLP

Application No. 10/821,925 Amendment dated October 3, 2005

Reply to Office Action of May 3, 2005

Docket No.: 4866-0101PUS1 Page 6 of 14

the outer diameter is 2-10 mm, and the a width ratio of the a concave part and the

with respect to a convex part is 1-10.

9. (Cancelled)

10. (Currently Amended) The stent according to Claim 1 Claim 2,

wherein the an outer wall of a left and right arm or the outer wall of the an

upper entrance have ring-shaped protruding rims, and the

wherein a long arm of the stent is fabricated into a larynx structure.

11. (Cancelled)

12. (New) The stent according to Claim 1, wherein the stent is formed by an

injection molding process or an extrusion blowing process.

Application No. 10/821,925 Amendment dated October 3, 2005 Reply to Office Action of May 3, 2005 Docket No.: 4866-0101PUS1 Page 7 of 14

AMENDMENTS TO THE DRAWINGS

The attached sheet(s) of drawings includes changes to:

Two sheets of revised formal drawings are attached to properly label FIGS. 2A-2E, 3A, and 3B. Also, reference numerals included in the specification are now shown in FIGS. 3A and 3B.